2025 Cardiology Intensive for Advanced Practice Providers

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners who care for patients with cardiology conditions.

Target Audience
This activity is intended for cardiology-focused nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses.

Learning Objectives
Upon completion of this activity, participants should be able to:

Leading With Impact: NPs and PAs at the Center of PAH Care Transformation

• Differentiate key pathophysiologic pathways involved in PAH, including right heart structure and function, and their implications for diagnostic strategies
• Evaluate the latest clinical safety and efficacy data for new and emerging PAH therapies to personalize treatment plans
• Assess patient response to treatment and determine when to escalate therapy, including the integration of combination therapy, to optimize treatment goals
• Leverage the unique role of an APP to bring quality of life, mental health, and shared decision-making into clinical practice to optimize patient treatment adherence and efficacy

ASCVD Prevention Through Individualized Pharmacologic and Supportive Care Management of Hyperlipidemia

• Plan individualized, guideline-recommended lipid-lowering treatment strategies using nonstatin or combination therapies to improve patient outcomes
• Design comprehensive, interprofessional, patient-centered care plans for individuals with or at risk for ASCVD that ensure optimal coordination and access for underserved patients
• Educate patients and caregivers on the clinical rationale for nonstatin or combination therapies to treat hyperlipidemia, addressing concerns on side effects and providing strategies to promote compliance

---

Agenda:

10:00 AM - 10:05 AM ET Welcome and Introduction
Moderator: John M. Giacona, PhD, PA-C

10:05 AM - 12:05 PM ET Leading With Impact: NPs and PAs at the Center of PAH Care Transformation
Presented by Brian P. Rose, PA-C, MPH, AACC and Lauren S. Eyadiel, PA-C, CCC-SLP, FHFSA, HF-Cert

• Gain practical, evidence-based strategies to enhance care for patients with pulmonary arterial hypertension. This interactive program equips NPs and PAs to recognize PAH earlier, apply the latest therapeutic advances, and lead collaborative, patient-centered management to improve outcomes.

Supported by an independent medical educational grant from Merck & Co., Inc., Rahway, NJ, USA.

12:05 PM - 12:10 PM ET Break

12:10 PM - 1:10 PM ET The Evidence on Obesity & CV Risk: Clinical Trials Meet Real-World
Presented by Lawrence Herman, DMSc, MPA, PA-C

• Understand that there is a need for obesity management that addresses the relationship between cardiovascular (CV) risk and obesity in appropriate adult patients with established CV disease. Analyze the efficacy and safety data from multiple randomized, controlled trials and explore complementary real-world evidence from routine clinical practice.

This non-CME educational program is sponsored by Novo Nordisk and managed by Decera Clinical Insights, formerly Clinical Care Solutions, a CEA Company.

1:10 PM - 1:15 PM ET Break

1:15 PM - 3:15 PM ET ASCVD Prevention Through Individualized Pharmacologic and Supportive Care Management of Hyperlipidemia
Presented by Laura Ross, PA-C, MPAS, CLS, DipACLM, AACC and Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert

• Discover practical, evidence-based strategies to optimize lipid management and reduce ASCVD risk. This interactive education equips NPs and PAs to individualize therapy, integrate nonstatin and combination treatments, and lead patient-centered care to improve cardiovascular outcomes.

Supported by an independent medical education grant from Novartis Pharmaceuticals Corporation.

3:15 PM - 3:20 PM ET Break

3:20 PM – 5:20 PM ET First to See, First to Act: Empowering NPs and PAs With Frontline Strategies to Recognize and Treat ATTR-CM
Presented by: Jill Stratford Waldron, MSN, GNP, MS

• Strengthen your skills in recognizing and managing transthyretin cardiac amyloidosis (ATTR-CM). Through expert-led discussions and practical case-based exercises, participants will learn to identify early clinical clues and apply emerging therapies to optimize patient outcomes.

This activity is supported by an educational grant from Alnylam Pharmaceuticals.

5:20 PM - 5:25 PM ET Closing Remarks
Moderator: John M. Giacona, PhD, PA-C